PMV Pharmaceuticals raised $50.8 million to advance its cancer drug development pipeline. $50.8 million funding directly supports core cancer drug push and materially improves financial runway.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | 1 | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2025 | ‡‡‡ |
|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 203.88 | 169.45 | 112.94 | 79.43 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 207.41 | 175.66 | 115.23 | 81.41 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 3.24 | 6.58 | 3.16 | 2.02 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 14.03 | 14.37 | 11.42 | 10.57 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (19.68) | (14.58) | — | — |
—
|
| ’25 | (18.27) | (18.30) | (19.82) | (17.19) |
(73.58)
|
| ’24 | (16.18) | (1.60) | (16.84) | (16.66) |
(51.28)
|
| ’23 | (15.01) | (12.90) | (15.66) | (12.08) |
(55.66)
|
| ’22 | (18.00) | (13.68) | (16.76) | (15.32) |
(63.76)
|
| ’21 | (12.90) | (9.24) | (12.40) | (12.03) |
(46.57)
|
| ’20 | (8.14) | (6.90) | (7.39) | (10.31) |
(32.74)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (19.68) | (14.58) | — | — |
—
|
| ’25 | (18.27) | (18.28) | (19.82) | (17.20) |
(73.57)
|
| ’24 | (16.78) | (1.60) | (16.81) | (16.49) |
(51.69)
|
| ’23 | (15.17) | (13.47) | (15.70) | (12.28) |
(56.62)
|
| ’22 | (18.79) | (17.18) | (18.81) | (16.96) |
(71.74)
|
| ’21 | (13.02) | (9.71) | (12.90) | (12.29) |
(47.92)
|
| ’20 | (8.19) | (6.90) | (7.43) | (10.37) |
(32.89)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.34) | (0.34) | — | — |
—
|
| ’25 | (0.34) | (0.41) | (0.40) | (0.34) |
(1.48)
|
| ’24 | (0.30) | (0.02) | (0.37) | (0.45) |
(1.14)
|
| ’23 | (0.42) | (0.38) | (0.34) | (0.31) |
(1.44)
|
| ’22 | (0.41) | (0.38) | (0.40) | (0.43) |
(1.61)
|
| ’21 | (0.26) | (0.29) | (0.33) | (0.41) |
(1.28)
|
| ’20 | (0.16) | (0.18) | (1.46) | 3.53 |
(2.40)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.13 | 1.18 | 1.40 | 0.81 | — | — | — |
Low Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 24.27 | 9.72 | 3.47 | 1.84 | — | — | — |
High Price
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 62 | 63 | 47 | 54 | — | — | — |
Employees
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (73.33) | (68.96) | (74.81) | (79.91) | — | — | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (73.32) | (68.96) | (58.71) | (77.74) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.31) | (4.13) | (4.23) | (2.64) | — | — | — |
Depreciation
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | (1.61) | (1.44) | (1.14) | (1.48) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.40) | (1.16) | (0.99) | (1.40) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.18) | (0.02) | (0.01) | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.57) | (1.18) | (1.00) | (1.40) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.40 | 4.70 | 3.41 | 1.99 | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 45.60 | 48.02 | 51.58 | 52.54 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (63.76) | (55.66) | (51.28) | (73.58) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.98) | (0.96) | (0.40) | 0.00 | — | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (71.74) | (56.62) | (51.69) | (73.57) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 236.17 | 193.38 | 161.29 | 103.81 | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | 13.98 | — | — | — | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (227.90) | (203.88) | (169.45) | (112.94) | — | — | — |
Net Debt
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 246.03 | 225.69 | 176.08 | 104.71 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (24.36%) | (26.40%) | (26.48%) | (50.51%) | — | — | — |
ROA
|
| — | — | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (265.61%) | (229.63%) | (805.99%) | 0.00% | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (26.44%) | (29.24%) | (29.23%) | (55.37%) | — | — | — |
ROE
|
PMV Pharmaceuticals (PMVP), a clinical-stage biotech targeting p53-mutated cancers, trades at depressed levels after a 98% plunge from its 2021 peak, amid zero revenue, escalating losses, and high cash burn typical of pre-commercial developers. Despite the carnage—driven by rising rates, dilution from financings, and broader sector woes—analysts remain bullish, forecasting 260% to a staggering 1,341% upside based on potential Phase 2 successes for lead asset PC14586.
The balance sheet offers a silver lining with over $160 million in working capital and a net cash position providing 2-3 years of runway, even as free cash flow burns intensify and projections show minimal 2025 revenue alongside deeper losses through 2027. Insider activity raises flags, with heavy selling and no buys, contrasting the cash fortress amid eroding book value.
This high-stakes pivot point hinges on upcoming trial data and milestones that could spark partnerships, approvals, or buyouts—unlocking multi-bagger returns—or lead to further dilution and downside. For risk-tolerant investors, PMVP embodies biotech’s boom-or-bust allure.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.